

CLAIMS

1. A combination for the treatment of pain comprising an alpha-2-delta ligand and an atypical antipsychotic, or pharmaceutically acceptable salts thereof.
- 5 2. A combination according to claim 1 or 2, wherein the alpha-2-delta ligand is selected from gabapentin, pregabalin, [(1R,5R,6S)-6-(Aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1-Aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-Tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (1 α ,3 α ,5 α)(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid, (3S,5R)-3-Amino-5-methyl-octanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline and (2S,4S)-4-(3-fluorobenzyl)proline, or a pharmaceutically acceptable salt thereof.
- 10 3. A combination according to claim 1 or 2, wherein the alpha-2-delta ligand is gabapentin.
- 15 4. A combination according to claim 1 or 2, wherein the alpha-2-delta ligand is pregabalin.
- 20 5. A combination according to any one of claims 1-4 wherein the atypical antipsychotic is selected from ziprasidone, olanzapine, clozapine, risperidone, sertindole, quetiapine, aripiprazole, asenapine, amisulpride, (3R,4R,5R)-3-amino-4,5-dimethyl-heptanoic acid and (3R,4R,5R)-3-amino-4,5-dimethyl-octanoic acid, or a pharmaceutically acceptable salt thereof.
- 25 6. A combination according to any one of claims 1-5 where the atypical antipsychotic is ziprasidone.
- 30

7. A pharmaceutical composition for the curative, prophylactic or palliative treatment of pain comprising a therapeutically effective amount of a combination according to any one of claims 1-6, or pharmaceutically acceptable salts thereof and a suitable carrier or excipient.
8. Use of an alpha-2-delta ligand in combination with an atypical antipsychotic, or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the curative, prophylactic or palliative treatment of pain.
9. Use according to claim 8 where the pain is neuropathic pain.
10. A method for the curative, prophylactic or palliative treatment of pain, comprising simultaneous, sequential or separate administration of a therapeutically amount of an alpha-2-delta ligand and an atypical antipsychotic, or pharmaceutically acceptable salts thereof, to a mammal in need of said treatment.
11. The method according to claim 10 where the pain is neuropathic pain.
12. A product containing and alpha-2-delta ligand and an atypical antipsychotic, or pharmaceutically acceptable salts thereof, as a combined preparation for simultaneous, separate or sequential use in the treatment of pain.